Introduction: As an improvement upon Solid Lipid Nanoparticles (SLNs), nanostructured lipid carriers (NLCs) represent novel drug delivery platforms that have been developed to address the shortcomings of SLNs; most notably, limited drug loading and poor drug delivery system stability. Methods: A literature search was performed using several electronic scientific databases, such as PubMed, Scopus, Web of Science, and ScienceDirect, for articles published between 2015 and 2025 to identify relevant literature on NLCs. Results: The optimized NLC formulations exhibited mean diameters in the range of 40-300 nm, while the surface charge ranged approximately ± 30 mV. The drug loading efficiencies of the NLC formulations were found to reach up to 20 % (w/w), and greater than 90 % of the drug was retained within the NLCs after extended periods of time. Discussion: Despite offering significant benefits to drug delivery, there are a number of issues that need to be addressed prior to successful clinical implementation of NLCs, including the effects of lipid polymorphism, the long-term stability of NLCs, and the scalability of NLC production. Conclusion: This review highlights the multifaceted progress in NLC development, with emphasis on material innovations and their translational relevance in modern pharmaceutics.
Kumar et al. (Wed,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: